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Abstract
Macrophages are important drivers of pathogenesis and progression to AIDS in HIV infec-
tion. The virus in the later phases of the infection is often predominantly macrophage-tropic
and this tropism contributes to a chronic inflammatory and immune activation state that is
observed in HIV patients. Pattern recognition receptors of the innate immune system are
the key molecules that recognise HIV and mount the inflammatory responses in macro-
phages. The innate immune response against HIV-1 is potent and elicits caspase-1-depen-
dent pro-inflammatory cytokine production of IL-1β and IL-18. Although, NLRP3 has been
reported as an inflammasome sensor dictating this response little is known about the pattern
recognition receptors that trigger the “priming” signal for inflammasome activation, the NLRs
involved or the HIV components that trigger the response. Using a combination of siRNA
knockdowns in monocyte derived macrophages (MDMs) of different TLRs and NLRs as well
as chemical inhibition, it was demonstrated that HIV Vpu could trigger inflammasome activa-
tion via TLR4/NLRP3 leading to IL-1β/IL-18 secretion. The priming signal is triggered via
TLR4, whereas the activation signal is triggered by direct effects on Kv1.3 channels, causing
K+ efflux. In contrast, HIV gp41 could trigger IL-18 production via NAIP/NLRC4, indepen-
dently of priming, as a one-step inflammasome activation. NAIP binds directly to the cyto-
plasmic tail of HIV envelope protein gp41 and represents the first non-bacterial ligand for the
NAIP/NLRC4 inflammasome. These divergent pathways represent novel targets to resolve
specific inflammatory pathologies associated with HIV-1 infection in macrophages.
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Author summary
It has been previously shown that inflammasome activation can be triggered during viral
infection to produce the active cytokines IL-1β and IL-18. Our study represents a signifi-
cant advance, as we now show that in fact there are distinct NLR inflammasome com-
plexes and viral ligands for IL-1β secretion (Vpu) compared to IL-18 secretion (gp41) in
response to HIV-1.
Most importantly, we show that the HIV envelope protein gp41 represents the first
non-bacterial ligand for the assembly of the NAIP/NLRC4 inflammasome. HIV gp41 is a
viroporin, and thus our data demonstrates for the first time that the NAIP/NLRC4
inflammasome assembles for all pore-forming proteins, irrespective of whether they
have a viral or bacterial origin. This is critical for the host antiviral response and has
broad implications for innate immunity in general.
Introduction
Although CD4+ T-cells might be the primary target of Human immunodeficiency virus
(HIV), cells of the myeloid lineage, such as monocytes, macrophages and mDCs are particu-
larly relevant cell types capable of being the target as well as the reservoir for HIV-1 infection.
They constitute a target for HIV, as they express both the primary receptor, CD4, as well as the
chemokine co-receptor CCR5 and thus are able to be infected by R5 tropic as well as dual
tropic strains of HIV. The significance of the infection of macrophages by HIV is well estab-
lished in the fact that as the infection progresses, CD4+ T-cells are depleted and individuals
become increasingly macrophage-tropic [1]; with macrophages becoming the main long-lived
HIV reservoir [2,3]. Independently to their role in infection, an additional role for monocytes/
macrophages and mDCs is emerging, where they contribute to a chronic immune activation
leading to pathogenic mechanisms associated with HIV. This dysregulated chronic immune
activation is the key factor in co-morbidities associated with HIV [4], such as cardiovascular
disease [5–7], HIV-associated neurological disorders [8], HIV-associated dementia (HAD) [9],
immune aging [10,11] as well as all-cause mortality [12,13]. This chronic inflammation is not
only observed in individuals who are not receiving anti-retroviral therapy (ART), but also in
individuals who show no detectable levels of HIV RNA in the absence of ART [14].
The mechanisms leading to HIV-associated chronic inflammation have not been fully elu-
cidated, but such potent inflammatory responses are most likely induced by the innate
immune system and the cells of the myeloid lineage armed with pattern recognition receptors
must be pivotal in binding and recognising microbial and danger molecules triggering potent
inflammatory responses.
There is accumulating evidence that HIV is able to trigger several pattern recognition
receptors (PRRs), including Toll like receptors (TLRs) [15,16] as well as the inflammasomes
[17], leading to secretion of pro-inflammatory cytokines, Interleukin-1β (IL-1β) and IL-18.
TLRs are type 1 transmembrane proteins that recognize pathogen-associated molecular pat-
terns, whereas inflammasomes are large cytoplasmic oligomeric structures that are formed by
members of the NOD-like receptor (NLR) family [18–20]. Inflammasome activation involves
a two-step process: a priming signal delivered by pattern recognition receptors (PRRs), such as
TLRs, which leads to the generation of pro-IL1β and pro-IL18 (Signal 1), and a second signal
(Signal 2) for the activation of caspase-1, which in turns cleaves pro-IL1β and pro-IL18 and
induces the release of the active form of the pro-inflammatory cytokines. In this way, the
inflammasome acts as a signalling platform for inducing caspase-1 activation, which further
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leads to maturation and secretion of IL-1β and IL-18 [21]. IL-1β is one of the major cytokines
that modulate the host response to intracellular pathogens, including viruses [18]. IL-18 is
another critical anti-viral cytokine that is triggered by the host innate immune response in
order to increase the cytolytic potential of NK cells [22,23]. Although some inflammasome
sensors are capable of directly detecting pathogen associated molecular patterns (PAMPs),
most are indirect sensors of homeostasis altering molecular processes (HAMPs) [24]. NLRP3
for example detects a wide range of HAMPs associated with K+ efflux from the cell [25], while
the NAIP/NLRC4 inflammasome directly detects bacterial PAMPs, such as flagellin and the
type III secretion system [26].
In the case of HIV, it has been shown that HIV structural proteins can act as PAMPs for
TLRs and in particular TLR2 [15] and TLR4 [27,28], whereas its ssRNA triggers TLR7/TLR8
innate immune responses [16,29–31].
In addition, it has been shown that HIV-1 infection engages the NLRP3 inflammasome
complex [17,32], however the mechanisms that regulate IL-1β and/or IL-18 have remained
mostly unexplored. Questions that remain are how HIV triggers inflammasome activation?
What triggers Signal 1 and Signal 2 of inflammasome activation? Which TLRs and NLRs are
involved? Is the mechanism of IL-1β and IL-18 secretion in response to HIV identical?
Addressing these questions is of particular importance, especially since chronic raised serum
levels of IL-18 have been found in HIV patients and are associated with disease progression
and pathology [33]. It has been even suggested that they may contribute to virological treat-
ment failure in HIV-1-infected patients [33]. Given the central role that monocytes/macro-
phages play in the chronic inflammatory state and activation of the inflammasome observed in
HIV patients, this study has focused on the mechanisms of HIV-induced inflammasome acti-
vation in primary monocyte-derived macrophages (MDMs). Here we show that IL-1β induced
by HIV is predominantly regulated by the NLRP3 inflammasome, while IL-18 production is
predominantly regulated by the NAIP/NLRC4 inflammasome. In contrast to previous reports,
the mechanism of NLRP3 activation is from the action of Vpu, triggering K+efflux via Kv1.3
channels. Remarkably, NLRC4 is activated after NAIP directly binds to the HIV-1 viroporin
(pore forming viral protein) glycoprotein 41 (gp41).
Thus, this is the first report which shows NAIP/NLRC4 involvement in viral recognition in
MDMs, which could be conserved amongst pathogen pore-forming machinery. Our results
provide novel mechanistic insight into host recognition of HIV in MDMs, which are likely to
be critical determinants to the chronic immune activation associated with HIV-1 disease.
Results
HIV infection triggers inflammasome activation and IL-1β and IL-18
secretion
Given that IL-18 and IL-1β are elevated in the serum of HIV patients [34,35], we proceeded to
model this in vitro by measuring IL-1β and IL-18 secretion from primary infected monocyte-
derived macrophages (MDMs). We saw that HIV infection resulted in inflammasome activa-
tion and IL-1β and IL-18 secretion within 12 hr with an increase of IL-18 at 24 hr (Figs 1A and
S1). Inflammasome activation was further confirmed using confocal microscopy in order to
determine whether there is Apoptosis-associated speck-like protein containing a CARD
(ASC)-speck formation in response to HIV. ASC speck formation has a pivotal role in inflam-
masome assembly and activation. It was shown that HIV induced ASC speck formation of
NLRP3 and the adaptor molecule ASC in MDMs (Fig 1B).
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Fig 1. IL-1β and IL-18 secretion in HIV infection are differentially controlled. Monocyte derived macrophages (MDMs) (1 x 106) were
infected with HIV-1 (MOI = 1) or left untreated for 12hr and 24hr. Supernatant was collected post infection and analysed for IL-1β and IL-18
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HIV-induced “Signal 1” of inflammasome activation
Since inflammasome activation is a two-step process, comprising of 1) a priming signal deliv-
ered by PRRs, such as TLRs, and 2) an activation signal (Signal 2) for the activation of caspase-
1 which cleaves pro-IL1β and pro-IL18 and induces the release of the active form of the pro-
inflammatory cytokines; we sought out to investigate which PRR(s) trigger Signal 1. We pro-
ceeded to knock down using siRNA several TLRs and subsequently infect the knockdown cells
with HIV for 12h (Fig 1C). Since IL-18 has been shown to be constitutively expressed in the
blood monocytes of healthy humans [36], whereas IL-1β is not constitutively expressed under
homeostasis and it is induced in myeloid cells during stimulation with TLR ligands and other
cytokines [37], we proceeded to assess the generation of pro-IL-1β. It was shown that knocking
down TLR2, TLR4 and TLR8 inhibited the pro-IL-1β production (Fig 1C), suggesting that Sig-
nal 1 must be coming from those signalling PRRs.
In order to identify a specific inflammasome component regulating the cytokine produc-
tion observed, NLRP3, NLRP1, NLRC4 and NLRC5 expression was knocked down using
siRNA and cells were infected with HIV-1. As expected, IL-1β production was impaired when
NLRP3 was knocked down while silencing of NLRC5, NLRC4 or NLRP1 had no effect (Fig
1D). In contrast, silencing NLRP3 only had a partial effect on IL-18 levels, silencing NLRP1 or
NLRC5 had no effect, and we were surprised to see that silencing NLRC4 led to a large, signifi-
cant decrease in IL-18 production in the presence of HIV-1. When both NLRP3 and NLRC4
were silenced IL-18 production was returned to baseline. This demonstrates that secretion of
IL-1β and IL-18 is regulated differentially in response to HIV-1 (Fig 1D). This was further
shown by western blotting, where in the knockdown cells it was shown that pro-IL-1β was
induced in response to HIV and subsequently cleaved into the active form only when NLRP3
was expressed (Fig 1E and 1G); whereas pro-IL-18 was found as expected to be constitutively
expressed and to be cleaved into the active form only when NLRC4 was present (Fig 1F and
1H).
HIV viroporins trigger inflammasome activation
In order to determine which HIV component triggers inflammasome activation, we proceeded
to test HIV proteins which have been previously shown to trigger inflammatory responses.
MDMs were stimulated with HIV gp41, gp120 as well as Vpu in order to determine whether
the proteins themselves, and not the whole virus, can trigger IL-1β/IL-18 responses (S1A and
S1B Fig). Initially MDMs were stimulated with different concentrations of Vpu (S1A Fig) or
gp41 (S1B Fig) in order to determine the optimum concentration to use for our stimulations.
We also tested whether the transfection/vehicle reagent itself, Lyovec, was eliciting any
responses (S1C Fig), which was shown to be inert. In addition, in order to determine whether
the levels of HIV proteins upon infection by HIV reflected the levels of Vpu or gp41 used for
our stimulations, MDMs were lysed following either HIV infection (12 hr) or 12 hr stimulation
with different concentrations of Vpu/gp41 proteins and analysed by western blotting (S1D
secretion using ELISA kits (R&D Systems) (A). Confocal microscopy of ASC speck formation and oligomerisation of NLRP3 in MDMs in
response to HIV-1 (B). TLR2, TLR3, TLR4 or TLR8 expression in MDMs was knocked down using siRNA (80% inhibition of expression of TLRs)
and infected with HIV-1 for 12 hr and subsequently determined pro-IL-1β by ELISA (C). NLRP3, NLRP1, NLRC4, or NLRC5 expression in
MDMs was knocked down by siRNA (80% inhibition of expression of NLRs) and the cells were infected with HIV-1 for 12 hr and examined for
IL-1β, IL-18 (D), Graphs were normalized to the level of siRNA knockdown. Furthermore NLRP3, NLRP1, NLRC4, or NLRC5 expression was
knocked down by siRNA and the cells were infected with HIV-1 for 12 h and the presence of pro-IL1β, pro-IL18, and cleaved IL-1β and IL-18 was
investigated via western blotting (E). Quantification of relative levels of pro-IL-1β/IL-1818 and IL-1β/Il-18 was determined by densitometry using
Image Studio Lite (Licor) and normalized to internal control (β-actin) from 3 western blots (F). The data represent the mean of three independent
experiments ± SD (n = 3 sets of MDMs) yielding consistent results. ��, p< 0.005 and ���, p< 0.001 indicate statistically significant differences.
https://doi.org/10.1371/journal.ppat.1009417.g001
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Fig). When quantified by densitometry it was shown that when 100 ng/ml of Vpu/gp41 were
used, there was three times as much Vpu/gp41 protein when compared to the protein concen-
tration resulting from HIV infection (S1D Fig). In order to use a physiologically relevant con-
centration of the proteins for our experiments, we decided to utilise 50 ng/ml for all our
subsequent stimulations, which roughly equates to the protein levels that are found when the
cells are infected with HIV. To verify this, we either infected MDMs with HIV-1 for 12 hr or
stimulated MDMs with 50 ng/ml Vpu or gp41 and assessed IL-1β and IL-18 responses (S1E
Fig). It was shown that at this concentration, Vpu/gp41 elicited similar responses to the virus
itself.
Since we had established the concentration to be used for the proteins, we proceeded to
stimulate MDMs with HIV viroporins, It was shown that gp120 was not able to trigger inflam-
masome activation on its own, Vpu was found to be able to trigger both IL-1β and IL-18 in a
time-dependent manner, whereas gp41 was able to trigger only IL-18 production (Fig 2A and
2B). The inflammasome activation observed in response to Vpu and gp41 was further con-
firmed by the detection of the activated component of caspase-1, caspase-1 p20 (Fig 2C). Since
differences in the induction kinetics of IL-1β and IL-18 secretion in response to Vpu and gp41
were observed, we proceeded to perform a time course. It was shown that Vpu was able to
induce IL-1β as early as 4–8 h after stimulation, but this was rapidly diminished by 24–36 h
(S2A and S2B Fig). Whereas Vpu was able to induce IL-18 secretion much later, with secretion
picking at 24 h and being sustained up to 36 h (S1 Fig). As expected, gp41 was not able to trig-
ger IL-1β production, but it was able to trigger IL-18 secretion that was sustained for 36 h (S2
Fig).
In order to determine which PRRs might provide “Signal 1” of inflammasome activation
for these proteins, we proceeded to knockdown different TLRs. It was shown that none of the
TLRs tested provided the “priming” signal for gp41 (Fig 2D), whereas TLR4 and to a lesser
extent TLR2 provided the “priming” signal for Vpu (Fig 2E).
In order to determine whether gp41 can trigger “Signal 1” of inflammasome activation, we
looked at pro-IL-1β and pro-IL-18 expression in MDMs stimulated with either gp41 or Vpu.
Our results showed that pro-IL-18 was constitutively present in MDMs, however as expected
pro-IL-1β was not (Fig 2F and 2G). Vpu was able to induce pro-IL-1β and also cleaved IL-1β,
suggesting that it was able to trigger both signals of inflammasome activation (Fig 2F). On the
other hand, gp41 did not induce pro-IL-1β, but was only able to cleave the constitutively
expressed pro-IL-18 into active IL-18 (Fig 2G), suggesting a one-step inflammasome
activation.
In light of the effect of Vpu and gp41 in IL-1β and IL-18 production, we investigated their
effect on inflammasome activation by knocking down NLRP3, NLRC4 or NLRP1 using siRNA
in cells expressing either Vpu (Fig 2H–2J) or gp41 (Fig 2K–2M). When IL-1β and IL-18 secre-
tion as well as caspase-1 p20 expression was examined at 12 hr, the data showed a significant
reduction in IL-1β secretion as well as a reduction in caspase p20 expression when NLRP3 was
knocked down in cells expressing Vpu (Fig 2H–2J), while there was no significant change in
neither IL-1β (Fig 2H) or caspase 1 p20 (Fig 2J) when NLRC4 or NLRP1 were knocked down
(Fig 2H and 2J). Silencing NLRC4 showed a reduction of IL-18 in the presence of gp41 (Fig
2K), whereas silencing NLRP3 showed only a very small decrease (Fig 2K). When both NLRP3
and NLRC4 were silenced, IL-18 production was completely inhibited. To validate these
results, we also used pharmacological inhibition. We used the small molecule MCC950, a well-
known inhibitor for NLRP3 [38] to verify our findings (S2C Fig). Our data showed that pre-
treatment with NLRP3 inflammasome inhibitor MCC950 inhibited IL-1β in cells stimulated
with Vpu whereas it had no effect in cells stimulated with gp41 for 12 hr (S2C Fig). Since we
had seen that Vpu could trigger a delayed IL-18 production we repeated our experiments with
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Vpu for 24 hr as well (S2D Fig). Our data showed that MCC950 inhibited IL-1β and IL-18 Vpu
dependent secretion confirming that Vpu signals through NLRP3. In contrast, when stimu-
lated with gp41 for 24 hr there was no IL-18 inhibition confirming that gp41 does not trigger
IL-18 via NLRP3 (S2D Fig). In addition, we used a caspase-1 inhibitor, Ac-YVAD-cmk, which
abrogated IL-1β and IL-18 secretion at 12 hours (S2C Fig) confirming that the secretion of the
cytokines observed is caspase-1 dependent.
VSV-G pseudotyped HIV1 mutants lacking Env expression (HIV1Δenv) or lacking Vpu
(HIV-1 ΔVpu) were also used to infect macrophages for 12 hr. The results showed a reduced
IL-1β production in response to HIV-1 ΔVpu (S2E Fig) but a robust IL-18 response (S2F Fig),
whereas when HIV1Δenv was used we saw as expected a decrease in IL-18 production with
minimal change on IL-1β production (S2E and S2F Fig).
HIV-induced “Signal 2” of inflammasome activation
To discover how HIV infection can trigger “Signal 2” of inflammasome activation we utilised
inhibitors of several published inflammasome mechanisms including: lysosome disruption,
Cathepsin B inhibitor CA-074 [39,40]; production of reactive oxygen species (ROS), Dipheny-
liodonium (DPI) and N-acetylcysteine (NAC) [41], as well as Ca2+ mobilization [42], clathrin
mediated endocytosis, using Chloropromazine and siRNA against clathrin [17,43]. Our results
showed that none of these small molecule inhibitors had a significant effect on IL-1β and IL-18
secretion induced by HIV-1 (Figs 3A and S4).
One remaining mechanism proposed as the unifying basis for NLRP3 activation is potas-
sium or ion efflux [25]. In order to determine whether “Signal 2” was triggered via ion chan-
nels, we proceeded to utilise different ion channel inhibitors. Permeant Ca2+ chelator,
BAPTA-AM as well as ion channel inhibitors: 5-(N-ethyl-N-isopropyl) amiloride (EIPA) and
benzamil, (blocks Na+/H+ ion channels) tetraethylammonium (TEA), (a broadly acting
blocker of potassium (K+) channels), and verapamil, (blocks Ca2+ channels [44]) as well as
amantadine or rimantadine (blocks the influenza M2 channel [45]) were used. MDMs stimu-
lated with Vpu or gp41 were treated with different concentrations of each compound which
did not affect cell viability (viability of cells was determined by using 0.2% trypan blue and
examining cells under a microscope) (S3 Fig).
Cell-free supernatant was collected at 12hr post-stimulation and analysed for IL-1β (Fig 3B)
and IL-18 (Fig 3C). TEA and benzamil were successful in inhibiting IL-1β secretion but did
not inhibit IL-18 upon HIV-1 infection. There was no downregulation when verapamil, aman-
tadine or rimantadine were used. These results suggest that Vpu is selective for K+ monovalent
cations. Although our data demonstrated that Vpu seems to be selective for K+ monovalent
cations, it remains unclear whether the K+ channel blocker TEA prevents IL-1β secretion by
blocking Vpu and/or any other K+ channel. In order to address this possibility we generated a
Fig 2. HIV Vpu and gp41 play a role in inflammasome activation. Monocyte derived macrophages (MDMs) (1 x 106) were either left untreated
or transfected with 2μg of pVpu plasmid expressing Vpu or pgp41 or gp120 plasmid expressing gp120. Supernatants were collected and tested for
IL-1β and IL-18 secretion at 12 hr (A) and 24 hr (B). Cells extracts at 12 hr from mock or transfected cells were analysed for the presence of
caspase-1 p20 by western blotting, followed by quantification using Image Studio Lite (Licor) and normalized to internal control (β-actin) from 3
western blots(C). MDMs expressing gp41 (D) or Vpu (E) monocytes were silenced for TLR2, TLR3, TLR4 and TLR8 by siRNA. Supernatant was
collected at 12 hr and analysed for IL-1β and IL-18 using ELISA. Cell extracts of MDMs stimulated with either Vpu (F) or gp41 (G) were analysed
for the presence of pro-IL-1β, pro-IL-18, cleaved IL-1β or cleave IL-18 by western blotting, followed by quantification using Image Studio Lite
(Licor) and normalized to internal control (β-actin) from 3 western blots. MDMs expressing Vpu (H-J), gp41 (K-M) or pgmock (N-P) were
silenced for NLRP3, NLRP1, NLRC4 or NLRP3 and NLRC4 by siRNA. Supernatant was collected at 12 hr and analysed for IL-1β (Η,Κ, N) and IL-
18 (I,L,O) using ELISA. All graphs were normalized to the level of siRNA knockdown. Cells extracts were analysed for the presence of caspase-1
p20 at 12 hr by western blotting, followed by quantification using Image Studio Lite (Licor) and normalized to internal control (β-actin) from 3
western blots (J,M,P). The data represent the mean of three independent experiments ± SD (n = 3 sets of macrophages) yielding consistent results.
��, p< 0.005 and ���, p< 0.001 indicate statistically significant differences.
https://doi.org/10.1371/journal.ppat.1009417.g002
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Fig 3. Monovalent Ion channel inhibitors reduce IL-1β dependent inflammasome activation. Monocyte derived macrophages (MDMs) (1 x 106) were
infected with HIV-1 (MOI = 1) for 12 hr were also cultured in the presence or absence of Cathepsin B inhibitor (CA-074) (100 μM), DPI (20μM), NAC (20mM)
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VpuS24L mutant. This mutant is unable to form ion channels [46]. When we infected MDMs
with VpuS24L mutant, it was shown that VpuS24L failed to trigger IL-1β production (Fig 3D).
To determine the mechanism by which K+ efflux facilitates inflammasome activation in
HIV-1 infection we looked at different types of K+ channel blockers (4AP, Ba2+, Sotalol and
MgTx) due to their different blocking mechanisms and preference for different types of K+
channels. Sotalol blocks human ERG K+ channels, 4AP inhibits Kv channels, Ba2+ inhibits
inwardly rectifying K channels (Kirs) and Margatoxin (MgTX) blocks Kv1.3.as well as the spe-
cific Kv1.3 inhibitor GSK2332816A [47] (Fig 3E and 3F). Our results showed a great reduction
in IL-1β when we blocked Voltage-gated (Kv) channels especially the use of Kv1.3 inhibitor
GSK2332816A (GSK’816A) with EC50 value of 350 nM completely abrogated IL-1β production
(Fig 3E). These findings strongly suggest that HIV-1 Vpu exposure induces K+ through Kv1.3
channels; however, IL-18 production was not inhibited by Kv inhibitors (Fig 3F).
Vpu colocalization to the Kv1.3 microcluster is required for IL-1β
production
To elucidate the intracellular mechanism by which Vpu triggers K+ efflux to activate the
NLRP3 inflammasome we examined Vpu trafficking in the cell. Previous studies have shown
that the Vpu protein is transported predominantly to the rough endoplasmic reticulum
(RER)/ Golgi complex compartments [48], but has also been present in the recycling endo-
somes [49]. MDMs were transfected with pVpu for 12 hrs and permeabilised with 0.2% sapo-
nin. In order to visualise Vpu in our imaging experiments, an anti-Vpu antibody was used for
labelling. The Vpu protein mainly localised at the endoplasmic reticulum and Golgi complex
membranes (Fig 4A and 4B). The statistical significance of Vpu co-localisation with the Golgi
was calculated by Costes’ approach, using ImageJ which returned R(obs) of 0.715, which are
close to the theoretical maximal value suggesting that these co-localizations are highly signifi-
cant (Fig 4A and 4B). It is also known that Kv1.3 channels are expressed on the plasma mem-
brane and in the Golgi compartments in human astrocytes [50]. To determine whether this is
the case in macrophages, we looked at Kv1.3 distribution. Our data showed that Kv1.3 resides
in the Golgi R(obs) of 0.715 (Fig 4A) and moreover, it co-localises with Vpu, R(obs) of 0.689
(Fig 4B).
In order to obtain spatial information on Kv1.3 distribution we utilized structured illumi-
nation microscopy (SIM), which provides x and y axes resolution of ~140 nm and z axis reso-
lution of ~250 nm. SIM imaging demonstrated that Kv1.3 channels cluster in 200–300 nm
domains in the Golgi forming a microcluster (Fig 4C). Upon HIV-1 infection Vpu traffics to
the Golgi and targets these microclusters (Fig 4D).
Given the Vpu co-localisation to the Kv1.3 microclusters in the Golgi we investigated the
role of the Golgi apparatus in inflammasome activation by utilizing brefeldin A (BFA). The
fungal metabolite BFA has been known to induce rapid and reversible disassembly of the
Golgi stack into tubules and vesicles, resulting in the redistribution of Golgi-resident enzymes
and accumulation of proteins in the ER in a reversible manner [51,52].
chloropromazine (50μg/ml). Supernatants were collected and analysed for IL-1β and IL-18 using ELISA (A). MDMs stimulated with either Vpu (50 ng/ml) (B)
or gp41 (50 ng/ml) complexed with Lyovec (C)were pre-treated with and cultured in the presence of BAPTA-AM (15 μM), EIPA (25 μM), benzamil (50μM),
verapamil (50μM), amantadine (6.25 μM) or rimantadine (6.25 μM) or TEA (10mM) for 12 hrs. Supernatants were collected and tested for IL-1β (B) or IL-18
(C)) secretion using ELISA. IL-1β secretion in response to VpuS24L (D). In addition, MDMs stimulated with Vpu (50 ng/ml) or gp41(50 ng/ml) were treated
with and cultured in the presence or absence of MgTX (5nM), Ba2+ (300 mM), 4AP (1mM), Sotalol (100μM), GSK2332816A (350nM) for 12 hrs. Supernatants
were collected and tested for IL-1β (E) or IL-18 (F) secretion using ELISA. The data presented is the mean of three independent experiments ± SD �� p< 0.005
and ���, p< 0.001 indicate statistically significant differences.
https://doi.org/10.1371/journal.ppat.1009417.g003
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Treatment with BFA disassembled the Golgi and resulted in Vpu re-distribution (Fig 4E
and 4F), which blocked inflammasome activation by HIV-1 since there was no IL-1β produc-
tion in cells treated with BFA (Fig 4G). Quantification of these data using Costes’ approach
indicated that BFA caused a 70% reduction in the incidence of Vpu localization to the Golgi.
Taken together these observations indicate that Vpu recruitment to Kv1.3 microclusters in the
Golgi is essential for triggering IL-1β dependent signalling.
HIV-1 gp41 accumulates in lipid rafts and triggers NLRC4 via NAIP
To investigate how gp41 triggers a one-step inflammasome activation, we studied gp41 and
NRLC4 localisation. Studies have suggested that gp41 assembly occurs within lipid-raft struc-
tures especially at the edge of the raft [53]. More specifically the cytoplasmic domain of gp41
has been shown to interact with lipid rafts [54]. Therefore GM-1 ganglioside, a raft-associated
lipid, was detected using Alexa555-conjugated cholera toxin (CTX-B-Alexa555) and an anti-
rabbit gp41 antibody conjugated to Alexa488 was used to label gp41. Macrophages were
infected with HIV-1 and we proceeded to measure Fluorescence resonance energy transfer
(FRET) between gp41 (Alexa488-anti gp41) and GM-1 ganglioside (CTX-B-Alexa555) (Fig
5A). Large dequenching was observed once the Alexa555 was photobleached (E = 26±0.9%),
suggesting that gp41 concentrates in lipid rafts which contain GM-1 (Fig 5A).
In order to investigate the functional significance of lipid raft integrity we evaluated the
ability of HIV to trigger inflammasome activation when lipid rafts were disrupted with nysta-
tin, (a fungal metabolite that binds membrane cholesterol and disrupts raft integrity), or
MCD, (a compound that disrupts protein association with lipid rafts) were used. It was shown
that IL-18 secretion was inhibited by nystatin in a concentration-dependent manner (Fig 5B).
This highlights that gp41 localises to lipid rafts, which are essential for it to activate NLRC4. At
this point, it was not clear if NLRC4 directly detected gp41, or if this process requires the adap-
tor NAIP, which triggers NLRC4 activation in response to ligands such as flagellin and the
T3SS [55,56]. To determine whether NAIP interacts with gp41, fluorescence resonance energy
transfer (FRET) studies were performed. FRET can occur over 1–10 nm distances, and effec-
tively increases the resolution of light microscopy to the molecular level. Cells were infected
with HIV-1 and we proceeded to measure Fluorescence resonance energy transfer (FRET)
between gp41 (Alexa488-anti gp41) and NAIP (Alexa 546 anti NAIP). The results showed
strong associations between gp41 and NAIP (Fig 5A). We also analysed FRET between NAIP
and gp41 as well as NAIP and NLRC4 or NLRP3. Our results showed associations between
gp41 and NAIP (E = 24±1.1%) NAIP and NLRC4 (E = 20±0.7). There was no association
between NAIP and NLRP3 ((E = 6±0.8%).
Fig 4. Vpu targets Kv1.3 channels to induce inflammasome activation. Monocyte derived macrophages (MDMs) were transfected with pVpu at 24 h
post transfection cells were fixed and permeabilised in PBS/0.02% BSA, prior to fixation with 4% formaldehyde for 15 min. Cells were then stained with
GM130 mAb to label the Golgi, a rabbit anti-Vpu antibody to label Vpu or a Kv1.3 mAb followed by the appropriate secondary conjugated to Alexa
546 (red) or Alexa 488 (green). The nucleus was stained with TOPRO-3. Cells were imaged using a Zeiss 710 confocal microscope. Bars shown are
10 μm. The data presented are at least in 20 cells over four independent experiments. The merged images show extensive colocalization between Kv1.3
and the Golgi R(obs) of 0.715 as well as between Vpu and Kv1.3 R(obs) of 0.689 respectively (A,B). The degree of colocalization was determined using
ImageJ software via the Costes’ method. Data presented are representative images of n = 3 biological replicates, with at least 20 technical repeats.
Findings were consistent across all replicates. SIM super resolution imaging of Kv1.3 distribution at Golgi organelles is also shown. As well as Vpu and
Kv1.3 distribution in macrophages transfected with pVpu at 24 h post transfection (C,D). Quantification (right) of the relative fluorescence of the target
structures where regions of interest (ROI) were selected for the target areas are shown. The distribution/position of receptors was obtained with Zeiss
Zen black or ImageJ software. Cells transfected with pVpu at 24 h post transfection cells were treated with 10μg/ml Brefeldin. Golgi was stained with
Anti GM130 goat antibody conjugated to Alexa 546. An anti Vpu antibody conjugated to Alexa488 was used to label the Vpu protein. Anti Kv1.3 rabbit
polyclonal IgG was followed by donkey anti rabbit IgG-Alexa 633. Images of before and after treatment are depicted (E,F). Supernatants were also
collected and tested for IL-1β secretion using ELISA (G). The data presented is the mean of three independent experiments ± SD �� p< 0.005 and ���,
p< 0.001 indicate statistically significant differences.
https://doi.org/10.1371/journal.ppat.1009417.g004
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In order to investigate the functional significance of NAIP, its expression was knocked
down using siRNA in cells stimulated with gp41. It was shown that IL-18 secretion was signifi-
cantly impaired thus confirming the importance of NAIP in gp41 recognition (Fig 5C).
The interaction between gp41 and NAIP was further investigated in MDMs either infected
with HIV-1 or transfected with plasmid expressing gp41. The results showed that gp41 was co-
immunoprecipitated with endogenous NAIP (Fig 5D). Thus, NAIP associated with gp41 only
in the presence of an HIV-1 infection.
Furthermore, we also used an alternative method to visualise the extent of NLRC4 and
NAIP clustering in the presence of gp41, as well as gp41 and NAIP interactions using the
super resolution microscopy method, stochastic optical reconstruction microscopy (STORM)
(39). This method overcomes the resolution limit of light microscopy, allowing localisation of
endogenous receptors to an accuracy of 10-30nm in fixed cells.
Cells were labelled with Fab fragments conjugated to the STORM compatible fluorophore
Alexa546 (red) or Atto 488 (green), we found that in the presence of gp41, NAIP and NLRC4
are both present forming densely packed nanoclusters that resemble a speck formation. Rip-
ley’s L-function analysis for the dSTORM images of gp41 molecules was performed for multi-
ple cells. Here, we observed a clear co-clustering of gp41 and NAIP molecules (Fig 5F). The
STORM data demonstrated that NAIP–gp41 complexes colocalize with NLRC4 providing fur-
ther evidence that upon HIV-1 infection, gp41 forms clusters with NAIP and NLRC4 where it
triggers inflammasome activation leading to IL-18 secretion.
HIV gp41 CT interacts with NAIP
HIV gp41 can be divided into three major domains: the extracellular domain or ectodomain,
the transmembrane domain (TM), and the cytoplasmic domain (cytoplasmic terminal tail
(CT)) [57]. It has been shown that the gp41 cytoplasmic tail (CT) which extends into the cyto-
plasm, is important in the viral replication, infectivity, cytopathogenicity, as well as mediating
association and targeting to lipid rafts [54].
The ectodomain, which comprises residues 511–684, can be further broken down into a
hydrophobic N-terminal domain termed the fusion peptide (FP) [58], the helical N-terminal
heptad repeat (NHR), C-terminal heptad repeat (CHR) [59] and a tryptophan-rich region
referred to as the membrane proximal external region (MPER) [60] that forms helical coiled-
coil structures linked by a disulfide-bridged loop (Fig 6A). The primary function of the gp41
ectodomain is to drive virus–cell membrane fusion.
The TM domain amino acid sequence is highly conserved among HIV isolates and contains
a conserved GXXXG helix–helix interaction motif and a highly conserved midspan arginine
Fig 5. NAIP interactions with gp41. Monocyte-derived macrophages (MDMs) (1 x 106) were infected with HIV-1 (MOI = 1), left untreated or
pre-treated with nystatin for 12 hr. Molecular interactions between gp41 and lipid raft (GM-1 ganglioside), NAIP, NLRC4 and NLRP3 were
assessed using Fluorescence resonance energy transfer (FRET) (A). MDMs stimulated with gp41 for 12 hr were treated with different
concentrations of nystatin. Supernatants were also collected and tested for IL-18 secretion using ELISA (B). MDMs silenced or not for NAIP and
then stimulated with gp41. Supernatant was collected and analysed for IL-18 using ELISA (C). Lysates from MDMs transfected with pgp41-FLAG
(Myc-DDK tag) were subjected to IP using anti-gp41 antibody or using control IgG or using anti FLAG (D, top panel) and then analysed by
western blotting using anti-NAIP antibody. Lysates from MDMs infected with HIV-1 were subjected to IP using anti-gp41 antibody or using
control IgG (D, bottom panel) and then analysed by western blotting using anti-NAIP antibody. (D) The data presented is the mean of three
independent experiments ± SD �� p< 0.005 and ���, p< 0.001 indicate statistically significant differences. Super-resolution images of gp41 and
NAIP as well as NAIP and NLRC4 in cells infected with HIV-1 are also shown (E) Cells were labelled with anti gp41-Atto488 (green), anti
NAIP-Alexa546 (red) (top panel) or anti NLRC4-Alexa546 (red) and anti NAIP–Atto488 (green) (bottom panel), fixed, imaged, and processed
for dSTORM. Colocalization of receptors is presented in arbitrary units (AU) as mean fluorescence intensity of the red and green signal.
Representative regions (right) of the relative fluorescence of the target structures where regions of interest (ROI) were selected for the target areas
is also shown and co cluster analysis using bivariant Ripley’s L function. The distribution/position of receptors was obtained with Zeiss Zen black
and ImageJ software.
https://doi.org/10.1371/journal.ppat.1009417.g005
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residue. The classical structural view of the TM is that of a single membrane-spanning a-helix
[57].
To further understand the nature of gp41 and NAIP interactions and reveal gp41 domains
that promote these interactions, we thus utilised peptides derived from gp41 sequence as well
as gp41mutants with different sequence deletions (Fig 6B).
In this study, the binding of NAIP and gp41 was analysed by the BIAcore system. NAIP was
covalently coupled through amino groups to dextran that was immobilized on the surface of
the BIAcore sensor chip. Various concentrations of gp41 mutants (500ng, 1μg, 5μg, 10μg)
were repeatedly injected over the immobilized protein and flagellin was used as a positive con-
trol. The sensograms were monitored as shown in Fig 6B. Our results showed that NAIP has
an affinity for gp41 CT with an affinity constant (KD) 4.13x10-10, whereas there was no bind-
ing with the ectodomain, or the transmembrane domain (see Table 1). Thus, confirming that
the region of gp41 between 707 and 856 amino acid residues is important for NAIP
recognition.
Discussion
Anti-retroviral therapy has changed the lives of individuals infected with HIV from a death
sentence to a chronic condition. As the disease phenotype changes to a chronic one, it has
become apparent that the viral tropism and cellular targets also change. The R5-tropic HIV
dominates in the early stages of CD4+ T-cell infection while X4-tropic virus emerges in
advanced disease targeting monocytes/macrophages and mDCs [61]. Monocytes and macro-
phages are not only providing target and reservoir for HIV-1 infection in the later stages of the
disease, but they trigger a chronic immune activation that leads to the pathogenic mechanisms
associated with HIV-1 disease [62,63]. Pattern recognition receptors, such as the TLRs and the
inflammasomes on monocytes/macrophages are key in triggering this inflammatory response.
In particular, IL-18, which results from inflammasome activation, has been shown to be raised
in the serum of individuals with advanced clinical and immunological disease and associated
with virological treatment failure [33]. IL-18 seems to mediate upregulation of the HIV co-
receptor CXCR4 as well as TRAIL, which is a pro-apoptotic mediator in PBMCs [33] suggest-
ing that must be involved in CD4+ T-cell depletion and the pathogenesis of the disease.
In this study we focused on the mechanisms behind inflammasome activation in MDMs
and found that HIV can trigger both IL-1β and IL-18 upon infection. Since inflammasome
Fig 6. NAIP has an affinity for the CT domain of gp41. A schematic view of gp41 showing important functional regions, including the fusion peptide (FP),
the transmembrane region (TM)) and cytoplasmic tail (CT). The domains are drawn approximately to scale. (A), Estimation of NAIP binding affinity to
gp41 domains by the BIAcore system. NAIP protein was immobilized on the matrix of the chip and gp41 proteins were injected at flow rate 10 ml/min for
240 s. The binding ability of NAIP to each host protein was monitored and presented as a sensogram (plotted as RU versus time). For kinetic studies, gp41
proteins with increasing concentrations (500ng, 1μg, 5μg, 10 μg) were injected over the sensor chip. (B). Theoretical model of mechanisms of inflammasome
activation by HIV Vpu and gp41 (C).
https://doi.org/10.1371/journal.ppat.1009417.g006
Table 1. Binding constants of gp41 domains to NAIP. The binding affinity is expressed as KD.
Ligand Analyte NAIP Association rate constant Ka (1/Ms) Dissociation rate constant Kd (1/s) Binding affinity constant (Kd/Ka) KD (M)
Flagellin 3.97 x 104 9.81x10-7 2.47 x10-11
gp41 MPER NB, no binding detected
gp 41 ectodomain NB, no binding detected
gp41 V113 2.7 x101 3.53x10-3 1.31x10-4
gp41 CT 2.39x104 9.87x10-6 4.13x10-10
gp41TM/CT 4.35x104 6.91x10-5 1.59x10-9
https://doi.org/10.1371/journal.ppat.1009417.t001
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activation is a two-step process, we investigated which PRRs trigger “Signal 1” in response to
HIV. TLR2, TLR4 and TLR8 were found to contribute to the “priming” of the MDMs, most
likely via either structural components (for TLR2/TLR4) and via ssRNA for TLR8[16]. When
we investigated which HIV component in particular is able to trigger the inflammasome acti-
vation it was shown that the HIV viroporin Vpu was able to trigger both IL-1β and a delayed
IL-18 response, whereas gp41 was able to trigger IL-18 secretion. More interestingly, Vpu
seemed to activate the NLRP3 inflammasome, whereas gp41 seemed to trigger NLRC4-in-
duced responses.
When we investigated how the HIV proteins triggered “Signal 1” of inflammasome activa-
tion, it was found that the viroporin Vpu was able to induce pro-IL-1β production via mainly
TLR4, whereas although gp41 was able to trigger inflammasome activation, it did not trigger a
“priming” signal.
Previous studies have shown that distinct regulatory mechanisms can control IL-18 and IL-
1β. Zhu and Kanneganti [64] have previously demonstrated that there is a difference in the
transcription of IL-1β and IL-18 in BMDMs. Therefore, it seems that IL-1β and IL-18 are dif-
ferentially regulated, not only by different inflammatory signals (as in the case of Zhu and Kan-
neganti), but also with HIV ligands as in our study. In addition, the kinetics of activation were
different. IL-1β was induced by Vpu but not sustained for long, whereas IL-18 was induced
later on and sustained for longer. This is agreement with Zhu and Kanneganti and explains
why there is a sustained chronic cleaved IL-18 in the serum of HIV patients.
Our results demonstrate that there is not only distinct regulatory mechanisms that control
IL-1β and IL-18 production during HIV infection, but that HIV components are able to trigger
different components of the innate immune sensing machinery.
HIV Vpu has the capacity to induce pro-IL-1β production and to subsequently activate cas-
pase—cleavage resulting in secretion of IL-1β and a delayed IL-18 response via NLRP3 activa-
tion. Therefore, Vpu is able to trigger both “Signal 1” via mainly TLR4 as well as “Signal 2” of
inflammasome activation. Vpu is a class IA viroporin that is mainly located at the Endoplasmic
reticulum (ER) and Golgi disrupting ionic balances and is able to trigger “Signal 2” via ion
flux. [65] (Fig 6C). With the use of ion channel inhibitors as well as specific K+ ion channel
inhibitors we have demonstrated that Vpu causes K+ efflux possibly via membrane depolariza-
tion in the Golgi. This K+ efflux is mediated by opening of Kv1.3 ion channels which facilitate
the maturation and release of IL-1β and a delayed IL-18 response. It remains to be determined
whether Vpu interacts with the channel protein directly causing the channel to open or
whether the effect on Kv activity is indirect.
On the other hand, our results provide evidence that HIV-1 gp41 activates the NAIP/
NLRC4 inflammasome and triggers mainly IL-18 production. HIV gp41 does not trigger a
“priming signal” but rather uses a “one-step” inflammasome activation by directly interacting
intracellularly with NAIP/NLRC4. HIV gp41 is similar to type III secretion rod and needle
proteins, in that it disrupts plasma membrane integrity and regulation and is recognized by
NAIP via its conserved hydrophobic cytoplasmic domain. This conserved mechanism pro-
motes NAIP interaction with NLRC4 and formation of an oligomeric NLRC4 inflammasome
complex, resulting in activation of caspase-1 and IL-18 secretion. This is the first study show-
ing that human NAIP can recognize viral proteins. Thus, we can conclude that NAIP likely
acts as a broad-spectrum innate immune surveillance system that detects microbial proteins
from bacteria and viruses which disrupt membrane stability. Given that diverse viruses likely
utilize conserved mechanisms for directing viroporin incorporation into the cell and the ability
of RNA viruses such as influenza virus and HIV to utilise lipid rafts for assembly, and cell
entry there could be a much broader range of NAIP detection than previously thought [66–
68].
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Interestingly, localisation of gp41 to lipid rafts seems to be required for NAIP activation.
This is unusual as most NAIP ligands are soluble, but its association with non-soluble ligands
has previously been reported. In particular one of tis ligands in Shiga-toxigenic E.coli 0113:
H21 strain, flagellin (which is a NAIP ligand) has been shown to mediate invasion which is
lipid-raft-dependent [69]. On the other hand, topology of HIV gp41 C-terminus, which we
have identified as the ligand for NAIP, is proposed to be either completely intracytoplasmic or
with an extracellular position. Therefore, it could be that there is a transient exposure of gp41
C-terminus in lipid rafts during membrane fusion. Its concentration within lipid rafts could
cause lipid dysregulation and internalization, subsequently interacting with NAIP (Fig 6C);
what is even more interesting is that gp41 has been previously shown to directly interact with
other host proteins intracellularly, in particular TAK1 [70].
Our results highlight the divergent production of IL-1β and IL-18 by Vpu and gp41 from
HIV-1, which could account for different inflammatory manifestations during HIV infection.
This discordant/staggered activation of inflammasome cytokines could be crucial for the trig-
gering of chronic HIV-1 inflammation and immune activation in the development of non-
AIDS conditions such as cardiovascular, respiratory and neurologic diseases which leads to
increased mortality in HIV-1 positive patients [71,72]. The early, IL-1β production in response
to Vpu could be beneficial for the clearance of the virus, whereas the delayed IL-18 response
via Vpu and gp41 could have detrimental effects for CD4+ T-cells. Since IL-18 has been shown
to increase CXCR4 expression as well as the apoptosis TRAIL in PBMCs of HIV patients, it
would suggest that raised IL-18 must promote viral replication (thus impaired response to
ART) and apoptosis and subsequent depletion of CD4+ T-cells leading to chronic inflamma-
tion and immune activation. Therefore, virological treatment failure and persistent IL-18
raised levels could be due to discordant innate immune recognition of gp41, lending support
to possibly targeting IL-18 in HIV patients [73]. Our novel mechanistic insight sheds light on
the mechanisms by which HIV-1 produces these cytokines, defining targets that could be rele-
vant in the fight against HIV-1 mediated pathology.
Methods
Virus production and infectivity assay
HIVNL4-3 (X4-tropic) and HIV-1 R8Bal (R5-tropic) were prepared by transfection of 1×106
293T cells per well in a 24-well plate with 1 μg of the appropriate full-length infectious HIV
plasmid using the FuGene6 transfection reagent (Roche). Virus-containing supernatants were
passed through a through 0.45 μm pore-size nitrocellulose membrane (Spin-X; Corning) filter
to remove cellular debris and precipitated in polyethylene glycol at 4˚C. Precipitated virus was
then centrifuged at 14,000 g for 20 minutes, re-suspended in PBS, and frozen at −80˚C until
use.
HIV-1 pseudotyped viruses were generated as follows: 293T cells were transfected with 100
ng of pNL4-3 ΔVpu (HIV ΔVpu) (NIH AIDS Reagents Program, NIBSC, UK) or pNLCH
Δenv (HIV Δenv) (ViiV Healthcare) or pNLCH-wtHIV (ViiV Healthcare) in the presence of
the pVSV-G envelope vector (vesicular stomatitis virus glycoprotein G), using GeneJuice
(MercK Millipore., USA). After 48 h, the supernatant was harvested, filtered through 0.22-μm
filters, collected and frozen at −80˚C until use.
The level of p24 protein in cell culture supernatants of HIV virus was determined by
p24-specific ELISA assay, performed by HIV-1 p24CA Antigen Capture Assay kit from AIDS
& Cancer Virus Program, which measures the amount of viral capsid protein in the superna-
tant. TCID50 of the viral stocks to determine the actual MOI was also performed.
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Human macrophages (1 x 106 per well) when infected with virus were incubated with (50ng
of p24, MOI = 1). For pharmacological inhibition studies cells were treated with inhibitors for
1hr before HIV-1 infection and then cultured in the presence of drugs.
Cell culture
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat by Ficoll-
Paque Plus. Primary human monocytes were isolated from PBMC using the Miltenyi Biotec
MACS magnetic cell separation system in order to isolate the CD14+ fraction From the
PBMCs or via negative selection using the easystep human monocyte enrichment kit (Stemcell
technologies). Monocytes were maintained in RPMI medium containing 10% FBS, and 1%
nonessential amino acids. Primary human macrophages were differentiated from monocytes
by culturing in medium containing 100ng/ml recombinant M-CSF (R&D systems) for 5 days.
Our experiments showed no difference in macrophages coming either from positive or nega-
tive selection.
The human biological samples were sourced ethically, and their research use was in accord
with the terms of the informed consents.
Drug optimization/Viability assays
Human macrophages were treated with drugs, EIPA, benzamil, and verapamil, MgTX, Sotalol
(at various concentrations for 12hr or 24hr). Drug-treated cells were then incubated with 0.2%
Trypan blue for 1min. Cells were washed three times with PBS, mounted onto glass slides and
viewed immediately on a Nikon microscope.
RNA interference
Primary monocyte differentiated macrophages (MDMs) were electroporated (nucleofection)
similar to a study by Gui et. al. [74] using the Human Macrophage Nucleofector Kit from Lonza
and the 4D Nucleofection core unit with 30pmol of control siRNA, or siRNA either for TLR2
(NM_003264–00074935 and NM_003264–00074937), TLR3 (NM_003265–00231804 and
NM_003265–00231806), TLR4 (NM_138554–00122250 and NM_138554–00122252), TLR8
(NM_016610–00064920 and NM_016610–00064925), NLRC4 (NM_021209/00184452 and
NM_021209/00184453), NLRP1 (NM_001033053/00151115 and NM_001033053/00151117)
NLRP3 (NM_001127461/00329604 and NM_001127461/00329605), NLRC5 (NM_032206/
00359503 and NM_032206/00191925) or NAIP (NM_004536/0056857 and NM_004536/
0056860). After 48 h the level of silencing was determined by western blotting. Electroporation
of human macrophages revealed high efficiency (40%) combined with low mortality. The cells
were then sorted by flow cytometry, evaluated with the Cellquest software (BD Biosciences,
San Jose, CA) to determine the proportion of fluorescent cells as described in [75]. In order to
achieve the same knockdown effect in all species of siRNAs, the experiments were performed
several times (in some cases we had to repeat 8 times to achieve the same level of knock down
as the other NLRPs. All siRNAs used were Mission siRNAs from Sigma.
Fluorescence resonance energy transfer
FRET is a non-invasive imaging technique used to determine molecular proximity. FRET can
occur over 1–10 nm distances, and effectively increases the resolution of light microscopy to
the molecular level. FRET was measured in terms of dequenching of donor fluorescence after
complete photo-bleaching of the acceptor fluorophore. Increased donor fluorescence after
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complete destruction of the acceptor indicates association between the two molecules of
interest.
Confocal microscopy
Monocytes or differentiated macrophages were nucleofected with 2 μg of pVpu, at 24 h post
transfection cells were rinsed twice in PBS/0.02% BSA, prior to fixation with 4% formaldehyde
for 15 min. The cells were fixed in order to prevent potential re-organisation of the ‘proteins
during the course of the experiment. Cells were permeabilised using PBS/0.02% BSA/0.02%
Saponin and labelled with antibodies for NLRC4, NLRP3 directly labelled with the appropriate
fluorophore. We have validated our confocal experiments with isotype control antibodies as
well as with only secondary antibody. Furthermore NLRP3, NAIP and NLRC4 antibodies have
been validated for non-specific binding by using NLRP3, NAIP and NLRC4 knockdown cells
respectively (S2 Fig). The results showed no nonspecific binding.
Cells were imaged on a Carl Zeiss, Inc. LSM510 META confocal microscope (with an Axio-
vert 200 fluorescent microscope) using a 1.4 NA 63x Zeiss objective. The images were analysed
using LSM 2.5 image analysis software (Carl Zeiss, Inc.).
In order to quantify the degree of co-localization, we used ImageJ software (MacBiopho-
tonics). The analysis uses Costes’ approach. This allows for the calculation of Pearson’s correla-
tion coefficient R(obs), which also accounts for any random overlay of pixels by generating the
mean correlation coefficient R(rand) between n images that have identical average pixel inten-
sity to the original images, but a random distribution of pixels. Costes’ randomisation method
calculates the statistical significance of the Pearson’s correlation coefficient. It returns a signifi-
cance (p-value) expressed as a percentage.
Cytokine assays
Cell supernatants were collected after each stimulation and frozen until the assays were per-
formed. The IL-18, human IL-1β ELISA (Human IL-1-beta/IL-1F2 DuoSet ELISA) and pro-
IL-1β kits (R&D systems) were used.
Co-immunoprecipitation assays
Macrophage cells lysates were prepared by lysing cells with buffer (50 mM Tris-HCl, pH 7.5,
50 mM Nacl, 0.1% NonidetP40, 1 mM MgCl2, 1mM CaCl2 and 2mM PMSF). Lysates were
immunoprecipitated with anti gp41, or control mouse immunoglobulin G (IgG) (Invitrogen)
or anti-Flag (anti Myc-DDK tag antibody) (Origene, USA) with Protein-A Sepharose (GE
Healthcare, Milwaukee, WI, USA).
Chemicals/antibodies/reagents
All fine chemicals were obtained from Sigma-Aldrich. Anti-caspase 1 p20 rabbit polyclonal
antibody, anti-NLRP3 rabbit polyclonal antibody (H-66), anti-NLRP3, goat polyclonal anti-
body (M-12) were purchased from Santa Cruz Biotechnology (CA, USA). Anti-Human NAIP
(CL541609) was from Thermofisher Scientific Ltd (USA). NAIP (ab25968) was from abcam,
anti-NLRC4 rabbit polyclonal (06–1125) was from Merck. Anti-NLRC4 mAb (F-3) was pur-
chased from Santa Cruz. Anti-GM130 mAb was from BD Biosciences, Anti-GM130 rabbit
polyclonal antibody (G7295) was from Sigma Aldrich. Anti-GM130 goat antibody conjugated
to Alexa 546 was from Abcam. Anti-Kv1.3 (G-9) mAb was from Santa Cruz, anti Kv1.3
(GTX16637) rabbit polyclonal IgG was from GeneTex. Anti-IL1β antibody (NBP1-42767) was
obtained from Novus (USA). Rabbit polyclonal to HIV1 gp41 (ab30755) and anti-Vpu
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antibody (ab81532) was obtained from Abcam. HIV-1 gp41, HIV-1 gp120 as well as HIV-1
anti-gp41 mAb (7H6) were obtained from the NIH AIDS Reagents Program, NIBSC, UK.
HIV-1 Vpu was obtained from Biosource. Expression clones for HIV-1 gp41 (pgp41), gp120
(pg120) and Vpu (pVpu) with a C-terminal myc-DDK tag were obtained from Origene, U.S.
A.
Macrophages were either stimulated with 50ng/ml of recombinant HIV-1 gp41, Vpu com-
plexed with lyovec from Invivogen (for internalisation) or transfected with 2 μg expression
clones pgp41and pVpu, with similar results.
The concentration of the recombinant proteins used were in accordance with a study by
Santosuosso et al. which had shown high levels of another envelope protein gp120 in patients
with chronic HIV infection52 (up to 2200 pg/ml gp120 in the peripheral blood of untreated
patients and 218ng/ml in lymph nodes of untreated animals).
Furthermore, a dose response of different concentrations of gp41 and Vpu was used to trig-
ger IL18 and IL1β secretion as well as determine cell toxicity using trypan blue prior to the
concentration selected for stimulation (S3 Fig).
In all the reagents used no endotoxin could be detected, using the Limulus amebocyte lysate
(LAL) assay.
Super-resolution microscopy
Super-resolution dSTORM were performed on a Zeiss ELYRA P.1 system (Carl Zeiss, USA).
Images were acquired with a Plan-Apochromat 633/1.40 oil immersion objective and an
Andor iXon 885 EMCCD camera. Fifteen images per plane (five phases, three rotations) and
0.125 mm z section of 3 mm height were required for generating super resolution images. Raw
images were reconstructed and processed to demonstrate structure with greater resolution by
the ZEN 2011 microscope software (Carl Zeiss,Germany). For cluster analysis, Ripley’s L func-
tion was determined using ImageJ.
Protein purification/expression purification of recombinant peptides
The NAIP protein was purified from human cell lysate using an NHS activated column conju-
gated to a NAIP antibody (LS-B455) in order to pull out NAIP from the cell lysate. The elution
buffer used was 100 mM triethanolamine pH 10. The pH of the eluted protein was adjusted to
pH 7 and was buffer exchanged via dialysis for 6hr at 4C with a buffer containing 50mM
Hepes,150mM NaCl, 5% Glycerol, 1mM DTT, 0.02mM ZnCl2.
In order to determine suitable buffer conditions, prior to buffer exchange a Protein Stability
screen from Molecular Dimensions (Newmarket, UK) had been used to provide information
on the effect of various environmental factors that will have on the denaturation or aggregation
of NAIP protein. The Durham pH Screen which deconvolutes buffer molecule (28 different
buffers) and pH effects pH (4–11) as well as the Durham Salt Screen (30 different salts), includ-
ing a range of lanathanides were included in the screen in order to determine the buffer used
for dialysis. A small amount of aggregated protein formed was removed by gel filtration. Prior
to use protein aggregation was determined by a fast high throughput plate based fluorometric
assay from Abcam. NAIP was buffer exchanged kept at 4˚C and was used within 24hr.
HIV gp41 recombinant peptides
gp41 FP, gp41 ectodomain, gp41(APR680), gp41MPER, gp41 (APR7022) were from the AIDS
Research Reagent Program NIAID, gp41CHR, gp41 P5181, gp41 P5079, gp41 TM/CT,
gp41V113 were custom made from Anaspec. The gp41 constructs were non glycosylated and
created analogously, by cloning the respective gp41CD sequences into vector pGEV. Sequence
PLOS PATHOGENS HIV triggers IL-1β and IL-18 secretion by different mechanisms
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009417 April 16, 2021 21 / 27
fidelity of constructs was verified by DNA sequencing. The recombinant plasmids were
expressed in E.coli and then purified.
Surface plasmon resonance (SPR) analysis
The interactions between gp41 and NAIP were analysed with a BIAcore 3000 (Uppsala, Swe-
den). The BIAcore system is equipped with the sensory chip CM5, a small metal chip with a
carboxymethyldextran surface, to allow ligand immobilization via native NH2. An amine cou-
pling kit containing N-hydroxysuccinimide (NHS), N-ethyl-N9-[(3-dimethylamino)-propyl]-
carbodiimide hydrochloride (EDC), and ethanolamine-HCl (Amersham Pharmacia Biotech)
was used to immobilize the ligand to the chip. The NAIP was immobilized on the sensory chip
CM5 to measure its interaction with different regions of gp41. The analyses of the kinetic
parameters were performed by using BIA EVALUATION 3.0, software designed to analyze
experimental sensor graph data for kinetics and affinity of interactions, according to the man-
ufacturer’s manual.
Supporting information
S1 Fig. A dose response using different concentrations of Vpu or gp41. A dose response
using different concentrations of Vpu (A) or gp41 (LyoVec was used as a vehicle) (B) were
tested on MDMs for IL-1β and IL-18 secretion using human IL-18 and human IL-1β ELISA
kits (eBiosciences) (A vehicle control was also performed (C). MDMs either infected with
HIV-1 for 12 hr or stimulated with 100 ng/ml Vpu or gp41 for 12 hr were lysed and cell lysate
was analysed for Vpu or gp41 protein levels using western blotting, followed by quantification
using Image Studio Lite (Licor) and normalized to internal control (β-actin) from 3 western
blots (D). Supernatants from MDMs either infected with HIV-1 for 12 hr or stimulated with
50 ng/ml Vpu or gp41 were assessed for IL-1β and IL-18 secretion using ELISA (E). The data
presented is the mean of three independent experiments ± SD �� p< 0.005 and ���, p< 0.001
indicate statistically significant differences.
(TIF)
S2 Fig. IL-1β and IL-18 secretion in response to HIV-1 Vpu and gp41. Monocyte-derived
macrophages (MDMs) (1 x 106) were stimulated with HIV-1 Vpu (50 ng/ml) (A) or HIV gp41
(50 ng/ml) (B) for 48 hrs. Supernatants were collected at 4, 8, 12, 24, 36 and 48 hrs and ana-
lysed for IL-1β and IL-18 using ELISA. The data presented is the mean of three independent
experiments. MDMs were pre-treated for 1 hr with NLRP3 inflammasome inhibitor MCC950
(0.01 μM) or Ac-YVAD-cmk caspase-1 inhibitor (10 μg/ml) and then stimulated with Vpu or
gp41 for 12 hr (C) or 24 hr (D). Supernatants were collected and tested for IL-1β and IL-18
secretion (C,D). HIVwt VSV-G and HIV 1 VSV-G pseudotyped mutants lacking Env expres-
sion. (HIV1Δenv) or lacking Vpu (HIV-1 ΔVpu) were used to infect MDMs for 12 hr. Super-
natant was collected and analysed for IL-1β (E) and IL-18 (F) using ELISA. The data represent
the mean of three independent experiments ± SD (n = 3 sets of macrophages) yielding consis-
tent results. ��, p< 0.005 and ���, p< 0.001 indicate statistically significant differences.
(TIF)
S3 Fig. A dose response using different concentrations of ion channel inhibitors. Mono-
cyte-derived macrophages (MDMs) (1 x 106) were stimulated with HIV-1 Vpu (50 ng/ml) and
different concentrations of ion channel inhibitors, such as EIPA (A), Benzamil (B), TEA (C),
BAPTA (D), Amantadine (E), Verapamil (F), Solatol (G), Ba2+(H), 4AP(I), MgTX(J), or
GSK’816A (K).
(TIF)
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S4 Fig. Effect of traditional inflammasome “Signal 2” inhibitors on HIV-induced IL-1β &
IL-18 processing. Monocyte-derived macrophages (MDMs) (1 x 106) were infected with HIV-
1 for 12 h in the presence or absence of Cathepsin B inhibitor (CA-074) (100 μM), DPI
(20μM), NAC (20mM) chloropromazine (50μg/ml) and the presence of pro-IL-1β, pro-IL-18,
cleaved IL-1β and cleaved IL-18 was investigated via western blotting.
(TIF)
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